All In Biotech

Free tool

FAERS Monitor: Defencath

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214520 or its brand name (Defencath, Heparin Sodium, Taurolidine). Reports on generic versions are filed under their own applications.

Reports

10

Serious

4

40% of reports

Hospitalization

3

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • device malfunction4
  • drug hypersensitivity3
  • complication associated with device1
  • device occlusion1
  • dialysis1
  • drug ineffective1
  • fall1
  • hypoxia1
  • infusion related reaction1
  • mental status changes1
  • occupational exposure to product1
  • panic attack1
  • paraesthesia oral1
  • product container issue1
  • product package associated injury1

Reports by year received

View as table
YearReports
20241
20252
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product package associated injury1944.1147.0235
occupational exposure to product1327.251.081
product container issue1245.438.260
device occlusion1149.523.336
dialysis1148.223.136
paraesthesia oral1145.822.735
complication associated with device1144.922.635
device malfunctionSignal4119.756.0361
mental status changes175.811.818
hypoxia159.79.314
panic attack157.79.013
drug hypersensitivitySignal332.612.764
infusion related reaction131.74.97
fall16.31.01
drug ineffective11.60.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.